Komori
Y

Yuki Gosei Kogyo Co.,Ltd.

4531Materials and ChemicalsMicro cap
365JPY+0.6%
★ Watch (sign-up required)
Price history
¥365Latest+37.2%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

A Japan-listed corporate group focused on fine chemicals, with integrated manufacturing and sales operations spanning amino acid-related products, chemical products and pharmaceuticals. The business comprises a single segment, with its core operations covering these 3 areas as well as contract manufacturing and related services. The group comprises 1 subsidiary and operates a distinctive manufacturing and sales structure across its business areas.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
40.1How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
0.6How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
1.5%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥8.0bnShare price × number of shares. The value of the entire company.
Equity ratio
51.9%The proportion of assets funded by money that does not have to be repaid.
Operating margin
1.0%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
13.4%The average annual growth in sales over the past three years.
What to watch next
Ramp-up and rising operating rates at the glycine capacity expansion facility at the Jōban Plant (investment of approximately ¥4 billion, scheduled for completion in March 2025)
From March 2025 onward (the ramp-up is expected to take several months on a quarterly basis)Impact HighLikelihood Medium
Disclosure and progress on specific projects under the new medium-term plan’s “expansion of the contract business in pharmaceuticals,” including contract manufacturing agreements, clinical trial drugs and generic active pharmaceutical ingredients
Primarily during fiscal 2026 (depending on the frequency of disclosures)Impact MediumLikelihood Medium
The impact of earnings-structure reforms, including cost reductions, SG&A reductions and supply-chain enhancements, reflected in financial results
From fiscal 2026 onwardImpact MediumLikelihood Low
The emergence of the impact of persistently high raw material and fuel prices and foreign exchange movements (yen depreciation/appreciation) on costs and earnings, or the success or failure of hedging and price pass-through
Ongoing (to be assessed at each quarterly earnings release)Impact MediumLikelihood High
The company’s response to the risk of procurement delays and insufficient supply volumes arising from geopolitical factors, including the situation in the Middle East
From fiscal 2026 onward, and when the risk materializesImpact LowLikelihood Medium
What to watch next
Loading
Who owns itTop holders total 39.1%
Listed holders 39.1%Everyone else 60.9%
NIPRO CORPORATION15.25%
NAGASE & CO.,LTD.5.08%
保土谷化学工業株式会社5.08%
Taiho Pharmaceutical Co., Ltd.3.11%
住友商事ケミカル株式会社2.48%
ZERIA PHARMACEUTICAL CO.,LTD.2.23%
ASKA Pharmaceutical Co., Ltd.1.69%
サンヨーファイン株式会社1.42%
2 other listed holders2.81%
Who owns it
HolderOwnership (%)
NIPRO CORPORATION15.25
NAGASE & CO.,LTD.5.08
保土谷化学工業株式会社5.08
Taiho Pharmaceutical Co., Ltd.3.11
住友商事ケミカル株式会社2.48
ZERIA PHARMACEUTICAL CO.,LTD.2.23
ASKA Pharmaceutical Co., Ltd.1.69
サンヨーファイン株式会社1.42
2 other listed holders2.81
This company's documents
Filings
Timely disclosures
Threads